Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
about
We are ageingCardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsCardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart diseaseDPP4 in DiabetesExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseCardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonistsNew insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-cateninPotential role of dipeptidyl peptidase IV in the pathophysiology of heart failureCardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapiesGLP-1 and cardioprotection: from bench to bedsideTargeting myocardial substrate metabolism in heart failure: potential for new therapiesIschaemic conditioning and targeting reperfusion injury: a 30 year voyage of discoveryRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsA systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesSitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoformsDPP4 deficiency preserved cardiac function in abdominal aortic banding ratsAlbiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiencyGLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle.GLP-1R-targeting magnetic nanoparticles for pancreatic islet imaging.Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsIncretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.GIP and GLP-1, the two incretin hormones: Similarities and differencesGLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.Targeting mitochondria to restore failed adaptation to exercise in diabetes.The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.Abscisic acid ameliorates atherosclerosis by suppressing macrophage and CD4+ T cell recruitment into the aortic wallElevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular diseaseDiabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapiesCardiovascular and hemodynamic effects of glucagon-like peptide-1.The stem cell adjuvant with Exendin-4 repairs the heart after myocardial infarction via STAT3 activation.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemEffects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model.Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation.Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cellsGLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.Potential role of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activity
P2860
Q21284533-D3FF4EE6-FD5B-4635-ACD5-F48477C996E9Q26749495-D16E36C4-7CA7-4F26-91D6-C67773762FE9Q26752255-C560B85F-558E-42E5-96ED-7F045FE50B0FQ26784211-B04CDD86-3E9E-4A56-AD3F-AC7756ED3296Q26797335-FF2F4458-F2ED-43A7-8623-39294FB6B13BQ26801173-C2A6B5F6-2452-4661-BA78-15F31B4A8545Q26823085-3B4584B8-4811-4A89-BB8E-13ED3C4AD511Q26823824-95DF2A6E-202C-458E-BAB4-980BFA36B10CQ26829634-F2383F6E-B1AF-4135-A678-C40BFE3DCB13Q26866958-28EAC24E-18CE-4BA1-AE34-524D11E43F34Q27024984-EAB71FF7-64F1-4CB3-B818-575E4EA1A737Q27694733-4499425F-A8E6-4811-99E1-992313C3C483Q28072918-42DD8650-540E-46E1-B5FF-4C9D3C5F2F79Q28081569-EE8989B2-AEF4-4CC6-A054-67E53E493001Q28282265-859787C9-173A-4C0C-8425-DCAC3350A668Q28535415-D28D43D1-6587-4D47-B00D-4A717C2DA0BEQ28538591-1C26E91A-E086-46F7-A1DC-6F7019C33F6EQ28740948-C133B780-55A4-4683-BC8C-58DD28C9EEC5Q30418716-6DC98B84-D82A-4A5A-A431-EA937D065232Q30588445-335814DC-BE4B-4F6B-9E8A-86BA5470EE29Q33521451-2E8A5F78-402E-46A5-AEB2-F2F517F3EFD7Q33602360-34753733-1CB0-43D7-B34B-EBDEAB385E08Q33603384-ACC0A278-3C0E-4A72-AA3F-450538F79036Q33609502-7CA57013-F5F4-470F-AFAD-574576BDE444Q33734024-4817480C-CD15-4AD0-9974-976BF7DCAEE5Q33750640-4FC12FC5-4D91-44BE-9C78-0F7D6FCE018DQ33919949-2209091D-5B09-47D5-A4C5-9A0F426DAB06Q33932817-4273F84A-5118-4E1E-96E6-0727A7FBF0F9Q33937727-37D63DC8-80F5-4722-A629-DBAD581CB547Q33939256-1896A57E-62BE-44BC-80BE-4E18E35D3A60Q33949425-1E7EB68D-41E6-4D7E-AAB5-2F420D3D8EE8Q33993725-DF35F710-0185-4BF7-8EAA-6944B9003D09Q34011497-F763E6F0-952E-464A-81FB-10E8DBB4F7A1Q34062829-3DF98977-F47A-46BC-A5FF-039872FC966EQ34128774-1522C8B1-5681-4F09-BBD4-50093F98CE8DQ34196210-33EA6CD4-FD30-4ADE-8A2F-45E73F625373Q34334364-095BE361-F1AC-4FB4-939D-8E7BB6D51F5AQ34336097-39613D00-0466-427E-BF54-8169E9CC3264Q34374321-F69278F5-D6B5-4339-A534-6FBBB7F95931Q34410188-5E790E16-CCEF-4B15-8295-5F9031074B93
P2860
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cardioprotective and vasodilat ...... ent and -independent pathways.
@en
Cardioprotective and vasodilat ...... ent and -independent pathways.
@nl
type
label
Cardioprotective and vasodilat ...... ent and -independent pathways.
@en
Cardioprotective and vasodilat ...... ent and -independent pathways.
@nl
prefLabel
Cardioprotective and vasodilat ...... ent and -independent pathways.
@en
Cardioprotective and vasodilat ...... ent and -independent pathways.
@nl
P2093
P1433
P1476
Cardioprotective and vasodilat ...... ent and -independent pathways.
@en
P2093
Judith Hoefer
M Hossein Noyan-Ashraf
Mansoor Husain
Steffen-Sebastian Bolz
P304
P356
10.1161/CIRCULATIONAHA.107.739938
P407
P577
2008-04-21T00:00:00Z